Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
QuintilesIMS
Healthtrust
Queensland Health
US Department of Justice
Covington
McKinsey
UBS
US Army
Mallinckrodt

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,383,678

« Back to Dashboard

Which drugs does patent 8,383,678 protect, and when does it expire?

Patent 8,383,678 protects EPANOVA and is included in one NDA.

This patent has twenty-three patent family members in twenty-one countries.
Summary for Patent: 8,383,678
Title:Type a gelatin capsule containing PUFA in free acid form
Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.
Inventor(s): Sachetto; Jean-Pierre (Arlesheim, CH), Bufton; Roly (Bubendorf, CH), Buser; Thomas (Nuglar, CH)
Assignee: Chrysalis Pharma AG (Sachseln, CH)
Application Number:12/984,994
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 8,383,678

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF HYPERTRIGLYCERIDEMIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,383,678

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0403247Feb 13, 2004

Non-Orange Book US Patents Family Members for Patent 8,383,678

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,960,370 Type A gelatin capsule containing PUFA in free acid form ➤ Subscribe
9,012,501 Type A gelatin capsule containing PUFA in free acid form ➤ Subscribe
9,729,321 Autonomous private key recovery ➤ Subscribe
9,132,112 Type A gelatin capsule containing PUFA in free acid form ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,383,678

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1755565 ➤ Subscribe
Japan 2014139216 ➤ Subscribe
European Patent Office 1755565 ➤ Subscribe
Japan 5435842 ➤ Subscribe
Japan 2012149073 ➤ Subscribe
Japan 2007522192 ➤ Subscribe
Israel 177462 ➤ Subscribe
Spain 2344208 ➤ Subscribe
United Kingdom 0403247 ➤ Subscribe
Denmark 1755565 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Boehringer Ingelheim
Express Scripts
Daiichi Sankyo
Merck
Johnson and Johnson
Accenture
US Department of Justice
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot